keyword
MENU ▼
Read by QxMD icon Read
search

prednisone

keyword
https://www.readbyqxmd.com/read/28097046/molecular-classification-of-tissue-from-a-transformed-non-hogkin-s-lymphoma-case-with-unexpected-long-time-remission
#1
Julie Støve Bødker, Marianne Tang Severinsen, Tarec Christoffer El-Galaly, Rasmus Froberg Brøndum, Maria Bach Laursen, Steffen Falgreen, Mette Nyegaard, Alexander Schmitz, Lasse Hjort Jakobsen, Anna Amanda Schönherz, Hanne Due, Linn Reinholdt, Martin Bøgsted, Karen Dybkær, Hans Erik Johnsen
BACKGROUND: The concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we retrospectively have analysed lymphoma tissue by exome sequencing and global gene expression in a patient with unexpected long-term remission following relaps. The goals were to phenotype the diagnostic and relapsed lymphoma tissue and evaluate its pattern. Furthermore, to identify mutations available for targeted therapy and expression of genes to predict specific drug effects by resistance gene signatures (REGS) for R-CHOP as described at http://www...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/28095160/minimal-loss-of-lifetime-for-patients-with-diffuse-large-b-cell-lymphoma-in-remission-and-event-free-24-months-after-treatment-a-danish-population-based-study
#2
Lasse Hjort Jakobsen, Martin Bøgsted, Peter de Nully Brown, Bente Arboe, Judit Jørgensen, Thomas Stauffer Larsen, Maja Bech Juul, Lene Schurmann, Linda Højberg, Olav Jonas Bergmann, Therese Lassen, Pär Lars Josefsson, Paw Jensen, Hans Erik Johnsen, Tarec Christoffer El-Galaly
Purpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission is important information for patients and for planning post-treatment follow-up. The purpose of this study was to evaluate the survival of patients with DLBCL in remission compared with a matched general population. Methods A total of 1,621 patients from the Danish Lymphoma Registry who were newly diagnosed with DLBCL between 2003 and 2011 were included in this study. All patients were ≥ 16 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like therapy...
January 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28094753/quantifying-cutaneous-adverse-effects-of-systemic-glucocorticoids-in-patients-with-rheumatoid-arthritis-a-cross-sectional-cohort-study
#3
Jonna Amann, Anne-Marie Wessels, Friederike Breitenfeldt, Dörte Huscher, Johannes W J Bijlsma, Johannes W G Jacobs, Frank Buttgereit
OBJECTIVES: EULAR guidelines state that adverse effects (AEs) of glucocorticoid (GC) therapy should be considered and discussed with the patient before treatment is initiated. However, reliable quantitative data, especially on cutaneous AEs of low-to-medium dose GCs are lacking. We performed a study assessing the occurrence of cutaneous AEs of GCs and its association with current and cumulative GC doses in patients with rheumatoid arthritis (RA). METHODS: In a cross-sectional study performed in 2 outpatient rheumatology centres, 381 RA patients were enrolled...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28088967/-a-phase-%C3%A2-dose-escalating-trial-of-pegylated-liposomal-doxorubicin-in-combination-with-cyclophosphamide-vincristine-and-prednisone-for-aggressive-non-hodgkin-lymphoma
#4
W N Shen, D M Ji, K Xue, Q L Zhang, F F Lyu, X N Hong, J N Cao, Y Guo
Objective: To explore the maximum tolerated dose of pegylated liposomal doxorubicin (PLD) in combination with cyclophosphamide, vincristine and prednisone as a modified CHOP regimen for aggressive non-Hodgkin lymphoma. Methods: Patients with newly diagnosed aggressive non-Hodgkin lymphoma were eligible for this trial. PLD was administered in cycle 1 and categorized into 4 dose level (30 mg/m(2), 35 mg/m(2), 40 mg/m(2), 45 mg/m(2) D1) according to a 3 + 3 approach for dose-escalation. Doxorubin was used in cycles 2-6...
December 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/28087868/mildly-pruritic-palmar-rash
#5
Amanda Gawin, Corey Lyon, Morteza Khodaee
After taking azithromycin and prednisone for lower respiratory symptoms, this patient developed a rash. The way it spread provided a diagnostic clue.
November 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/28079925/pregnancy-outcome-after-rituximab-treatment-before-conception-in-patients-affected-by-severe-pemphigus-vulgaris-superficialis
#6
C Vassallo, S Grassi, E Tagliabue, A Piccolo, V Brazzelli
Pregnancy is rare among patients affected by pemphigus, especially in European countries, mainly because of older patients, lower fertility rates and possible teratogenic risk.(1) Avoidance of immunosuppressive medications during pregnancy has been recommended, but inadequate treatment of pemphigus may increase morbidity and mortality.(2) Corticosteroids remain the first-line agent for treatment of pemphigus in pregnancy when low dosages are sufficient for disease control; however, prednisone and its metabolites crosses the placenta barrier, and high levels in the serum have been associated with adverse fetal outcomes...
January 12, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28078727/second-cancer-incidence-in-primary-mediastinal-b-cell-lymphoma-treated-with-methotrexate-with-leucovorin-rescue-doxorubicin-cyclophosphamide-vincristine-prednisone-and-bleomycin-regimen-with-or-without-rituximab-and-mediastinal-radiotherapy-results-from-a-monoinstitutional
#7
Vitaliana De Sanctis, Marco Alfò, Alice Di Rocco, Michela Ansuinelli, Eleonora Russo, Mattia F Osti, Maurizio Valeriani, Giuseppe Minniti, Lavinia Grapulin, Daniela Musio, Stefano Bracci, Alessandra Spagnoli, Maria Luisa Moleti, Vincenzo Tombolini, Maurizio Martelli
Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3...
January 12, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28076562/mycophenolate-mofetil-as-an-immunomodulator-in-refractory-noninfectious-uveitis
#8
Ever Ernesto Caso Rodriguez, Viviane Mayumi Sakata, Daniel Cesar Torres Melo Cavalcanti, Juliana Marques Zaghetto, Edilberto Olivalves, Carlos Eduardo Hirata, Joyce Hisae Yamamoto
Purpose: To evaluate the efficacy and tolerance of mycophenolate mofetil (MMF) for the treatment of noninfectious uveitis using the methods advocated by the Standardization of Uveitis Nomenclature (SUN) Working Group and to compare this with other studies of immunosuppression in ocular inflammation. Methods: Retrospective case series. Patients with noninfectious uveitis, followed at a tertiary Uveitis Service in São Paulo, Brazil, from 2007 to 2014 and receiving oral MMF for a minimum of 6 months, were retrospectively reviewed...
November 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/28074255/bortezomib-containing-regimens-bcr-for-the-treatment-of-non-transplant-eligible-multiple-myeloma
#9
Victor H Jimenez-Zepeda, Peter Duggan, Paola Neri, Jason Tay, Nizar J Bahlis
In multiple myeloma (MM) patients ineligible for transplant, the selection of up-front therapy needs to balance efficacy and toxicity. Recently, regimens with bortezomib, a proteasome inhibitor with anti-myeloma effects, have been reported. We aimed to evaluate the impact of different bortezomib-containing regimens (BCR) for the treatment of transplant-ineligible MM. All- consecutive patients treated with BCR at our institution from 01/05 to 02/16 were evaluated. With a median of 6 cycles, an overall response rate of 95...
January 10, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28073907/metformin-prevents-metabolic-side-effects-during-systemic-glucocorticod-treatment
#10
Eleonora Seelig, Stefanie Meyer, Katharina Timper, Nicole Nigro, Martina Bally, Ida Pernicova, Philipp Schuetz, Beat Muller, Marta Korbonits, Mirjam Christ-Crain
Objectives Patients receiving glucocorticoid treatment are prone to develop metabolic complications. In preclinical studies metformin prevented the development of the metabolic syndrome during glucocorticoid excess. We herein investigated the metabolic effect of metformin during glucocorticoid treatment in non-diabetic patients. Methods In a double-blind, placebo-controlled trial, patients starting glucocorticoid treatment (prednisone, prednisolone or methylprednisolone) for four weeks were randomized to concomitantly receive metformin (850mg once daily for one week followed by 850mg twice daily for three weeks) or placebo...
January 10, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28072956/-clinical-and-immunological-analysis-of-the-patient-with-autoimmunity-due-to-germline-stat3-gain-of-function-mutation
#11
Y Ding, Y Zhang, Y P Wang, H Y Zhao, X M Chen, X H Xue, X M Bai, Y F An, Z Y Zhang, X M Tang, X D Zhao
Objective: To investigate the clinical and immunological laboratory features and gene mutation in a female patient who carried a germline gain-of-function mutation in STAT3. Method: A patient with lymphadenopathy and pancytopenia, visited the Department of Rheumatology and Immunology of Children's Hospital of Chongqing Medical University in May 2016. The clinical and laboratory characteristics, results of immunophenotyping and exome sequencing were analyzed retrospectively and related literature was reviewed...
January 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/28072711/the-coexistence-of-sapho-syndrome-and-rheumatoid-arthritis-a-case-report
#12
Wenrui Xu, Chen Li, Weihong Zhang
RATIONAL: SAPHO (Synovitis-Acne-Pustulosis-Hyperstosis-Osteitis) syndrome is a rare disease featured by its dermatological and osteoarthritic disorders, the latter of which mainly affecting the anterior chest wall, spine, and sacroiliac joint. However, rheumatoid arthritis (RA) is a chronic autoimmune disease, mainly affecting the synovial tissue of small joints in hands and feet. Here, we present an extremely rare case diagnosed with both SAPHO syndrome and RA, with an onset interval of 10 years...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28070469/leukocytoclastic-vasculitis-with-systemic-involvement-associated-with-ciprofloxacin-therapy-case-report-and-review-of-the-literature
#13
REVIEW
Bruno Morgado, Catarina Madeira, Joana Pinto, Joana Pestana
A 71-year-old woman presented with constitutional signs and lower extremity palpable purpura after being prescribed a four-day course of 500 mg of ciprofloxacin two times daily for a gastrointestinal infection. She was admitted for inpatient treatment. During the third hospital day, she presented with an episode of abundant hematemesis while her skin lesions remained unchanged. Upper endoscopy revealed multiple lesions consistent with vasculitis and histological examination of the skin biopsy disclosed a leukocytoclastic vasculitis...
November 28, 2016: Curēus
https://www.readbyqxmd.com/read/28063195/first-line-non-cytotoxic-therapy-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer-a-systematic-review-of-ten-randomised-clinical-trials
#14
REVIEW
Michiel H F Poorthuis, Robin W M Vernooij, R Jeroen A van Moorselaar, Theo M de Reijke
OBJECTIVE: To systematically evaluate all available treatment options in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: We systematically searched PubMed, EMBASE, and the Cochrane libraries up to March 1, 2016 for peer-reviewed publications on randomised clinical trials (RCTs). RCTs were included if progression-free survival (PFS), overall survival (OS), quality of life (QoL), or adverse events (AEs) were quantitatively evaluated...
January 6, 2017: BJU International
https://www.readbyqxmd.com/read/28060985/-febrile-ulceronecrotic-mucha-habermann-disease
#15
Javier Arellano Lorca, Ignacio Yáñez Silva, Felipe Soto Vilches, Andrea Luna Heine, Yamile Corredoira Salum
Pityriasis lichenoides et varioliformis acuta (PLEVA), pityriasis lichenoides chronica (PLC) and febrile ulceronecrotic Mucha-Habermann disease (FUMHD) are considered different manifestations of the same disease. Febrile ulceronecrotic Mucha-Habermann disease is a rare, and potentially lethal illness which is characterized by fast progression of numerous papules that converge, ulcerate and form a plaque with a necrotic center, together with hemorrhagic vesicles and pustules that are associated with high fever and variable systemic symptoms...
September 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28059023/the-short-term-efficacy-of-bortezomib-combined-with-glucocorticoids-for-the-treatment-of-refractory-lupus-nephritis
#16
H Zhang, Z Liu, L Huang, J Hou, M Zhou, X Huang, W Hu, Z Liu
Objective The treatment of refractory lupus nephritis (LN) remains challenging for clinicians because these patients either do not respond to conventional therapy or relapse during the maintenance treatment period. The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients. Methodology Five refractory LN patients aged 21 to 43 years (four females and one male) with biopsy-proven diagnosis (four with type IV and one with type V+IV) were recruited...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28053548/recombinant-human-endostatin-in-combination-with-chop-regimen-for-peripheral-t-cell-lymphoma
#17
Qunling Zhang, Junning Cao, Kai Xue, Xiaojian Liu, Dongmei Ji, Ye Guo, Xiaonan Hong
Peripheral T cell lymphoma (PTCL) has a poor prognosis. Overexpression of vascular endothelial growth factor (VEGF) might contribute to the poor prognosis of PTCL and could be the target of novel therapy. The efficacy and safety of recombinant human endostatin (Endostar) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (ECHOP) have been explored in 15 PTCL patients. The objective response rate was 80%, with 53.3% patients having achieved complete response (CR) rate. The CR rate was 100% (3/3) in angioimmunoblastic T cell lymphoma (AITL) patients compared to only 36...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28053546/comparing-efficacy-and-survivals-of-initial-treatments-for-elderly-patients-with-newly-diagnosed-multiple-myeloma-a-network-meta-analysis-of-randomized-controlled-trials
#18
Xiaoping Liu, Jiarui Chen, Yuncen A He, Xiangyu Meng, Kaili Li, Colin K He, Shangqin Liu
OBJECTIVE: The aim of this study was to evaluate the efficacy and clinical outcome of initial therapies for elderly patients with multiple myeloma (MM). METHODS: Randomized controlled trials (RCTs) were obtained through a comprehensive search. Response rate, progression-free survival (PFS) and overall survival (OS) were the interested outcome measures. Network meta-analysis (NMA) using graph theory methodology to construct an NMA model, and sensitivity analysis were performed...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28050137/emerging-therapies-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma
#19
REVIEW
D MacDonald, A Prica, S Assouline, A Christofides, T Lawrence, L H Sehn
With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide-doxorubicin-vincristine-prednisone) or rituximab and cvp (cyclophosphamide-vincristine-prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28042138/the-efficacy-and-safety-of-docetaxel-based-chemotherapy-combined-with-dexamethasone-1-mg-daily-oral-administration-jmto-pca-10-01-phase-ii-trial
#20
Nobumichi Tanaka, Kazuo Nishimura, Eijiro Okajima, Kenji Ina, Osamu Ogawa, Hirohiko Nagata, Koichiro Akakura, Kiyohide Fujimoto, Momokazu Gotoh, Satoshi Teramukai, Yoshihiko Hirao
OBJECTIVES: Previously, one randomized control trial (TAX327) revealed the efficacy of docetaxel-based chemotherapy combined with prednisone. On the other hand, several studies showed a high prostate specific antigen (PSA) response with low-dose dexamethasone in castration-resistant prostate cancer (CRPC) patients. The objective of this study was to evaluate the efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone in CRPC patients. MATERIALS AND METHODS: This study was a single-arm multi-institutional phase II trial...
January 1, 2017: Japanese Journal of Clinical Oncology
keyword
keyword
8443
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"